Brief: Invivyd Announces Positive Initial Data From Ongoing Phase 1 Clinical Trial Of VYD222, A Monoclonal Antibody Candidate In Development For The Prevention Of Symptomatic Covid-19 In Immunocompromised People

Invivyd

22/06/2023 12:37

June 22 (Reuters) - Invivyd Inc  IVVD.O :
    * INVIVYD ANNOUNCES POSITIVE INITIAL DATA FROM ONGOING PHASE
1
CLINICAL TRIAL OF VYD222, A MONOCLONAL ANTIBODY CANDIDATE IN
DEVELOPMENT FOR THE PREVENTION OF SYMPTOMATIC COVID-19 IN
IMMUNOCOMPROMISED PEOPLE
    * INVIVYD INC: VYD222 HAS BEEN GENERALLY WELL-TOLERATED AT
ALL
DOSE LEVELS, WITH NO SERIOUS ADVERSE EVENTS REPORTED TO DATE
    * INVIVYD INC: EARLY SERUM SAMPLES FROM FIRST, LOWEST DOSE
COHORT
SHOWED STRONG NEUTRALIZATION ACTIVITY AGAINST OMICRON XBB.1.5
    * INVIVYD INC: INITIAL PHASE 1 DATA HELP SUPPORT ANTICIPATED
RAPID
TRANSITION TO A PIVOTAL CLINICAL TRIAL
    * INVIVYD INC: PLANS TO PRESENT ADDITIONAL RESULTS FROM
PHASE 1
CLINICAL TRIAL AT AN UPCOMING MEDICAL MEETING

Source text for Eikon:  ID:nGNXcgMVbL 
Further company coverage:  IVVD.O 

 ((reuters.briefs@thomsonreuters.com;))